Palabras clave
Cómo citar
Resumen
Presentar una serie de casos de COVID-19 con requerimiento de ingreso a Unidad de CuidadosIntensivos. La información fue tomada de las historias clínicas, y su evaluación y diagnóstico fue realizado mediante estudios paraclínicos en sangre, orina, PCR e imágenes diagnósticas en 4 pacientes con diferentes comorbilidades y nexo epidemiológico presente para desarrollo de la enfermedad. Los cuatro casosfueron manejados con cloroquina 300 mg vía oral, cada 12 horas, y azitromicina 1 gr vía oral, cada 24 horas, durante 5 días,sin complicaciones ni toxicidad asociada. El caso 1 desarrolló falla orgánica múltiple, incluyendo injuria renal aguda con una estancia en UCI de 4 días antes de su fallecimiento, mientraslos casos 2, 3 y 4 tuvieron una evolución favorable y fueron dados de alta de UCI. Se requieren estudios multicéntricos rápidos que orienten científicamente hacia un mejor abordaje diagnóstico y manejo, en el contexto de una enfermedad con un comportamiento clínico-epidemiológico que debe estudiarse en profundidad y que probablemente cobrará muchas vidas; además, debido a la ausencia de pruebas diagnósticas rápidas, la utilización de una clasificación basada en la severidad de lesiones radiológicas llamada CO-RADS (Covid-19 Imaging Reporting and Data System) podría ser de gran importancia para instalar de manera temprana los tratamientos farmacológicos disponibles y la asistencia respiratoria mecánica precoz.
Citas
World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/ dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.
Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirusfrom a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820. Available from: https://doi.org/10.1056/NEJMoa1211721
Wilde AH de, Snijder EJ, Kikkert M, Van MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2017;37:35. Available from: https://doi.org/10.1007/82
Müller MA, Corman VM, Jores J, et al. Mers coronavirus neutralizing antibodies in camels, eastern Africa, 1983-1997. Emerg Infect Dis. 2014;20(12):2093-2095. Available from: https://doi.org/10.3201/eid2012.141026
Organización Mundial de la Salud. Nuevo coronavirus- China.
Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis. 2020;18(March):20. Available from: https://doi.org/10.18332/tid/119324
Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. Am J Roentgenol. 2020;(1):1-6. Available from: https://doi.org/10.2214/ajr.20.22961
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061-1069. Available from: https://doi.org/10.1001/jama.2020.1585
Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama. 2020:1-8. Available from: https://doi.org/10.1001/jama.2020.5394
Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy. JAMA - J Am Med Assoc. 2020.
Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc. 2020;2019:3-6. Available from: https://doi.org/10.1001/jama.2020.2648
Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. Jama. 2020;2019:2019-2020. Available from: https://doi.org/10.1001/jama.2020. 4683 13. Salud instituto nacional de. Coronavirus (COVID - 2019) En Colombia. 2020.
Smithuis F, Smithuis R. 32 cases of suspected COVID-19 Imaging findings and follow up. Radiology Assistant.
World Health Organization (WHO). Coronavirus Disease 2019 (COVID-19) Situation Report – 82. 2020.
Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series. N Engl J Med. March 2020:NEJMoa2004500. Available from: https://doi.org/10.1056/NEJMoa2004500
Liu Y, Yan L-M, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;2019(20):2019-2020. Available from: https://doi.org/10.1016/S1473-3099(20)30232-2
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. Available from: https://doi.org/10.1016/s0140-6736(20)30566-3
Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020:1199-1207. Available from: https://doi.org/10.1056/nejmoa2001316
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. Available from: https://doi.org/10.1016/S0140-6736(20)30183-5
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. Available from: https://doi.org/10.1016/S0140-6736(20)30566-3
Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients with COVID-19. JAMA - J Am Med Assoc. 2020:1-2. Available from: https://doi.org/10.1001/jama.2020.3633
Wang T, Du Z, Zhu F, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 2020;395(10228):e52. Available from: https://doi.org/10.1016/S0140-6736(20)30558-4
Panitchote A, Mehkri O, Hasting A, et al. Factors associated with acute kidney injury in acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1). Available from: https://doi.org/:10.1186/s13613-019-0552-5
Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;(March). Available from: https://doi.org/10.1016/j.kint.2020.03.005
Volunteers A-2019-nCoV, Li Z, Wu M, et al. Caution on Kidney Dysfunctions of 2019-nCoV Patients. medRxiv.
:2020.02.08.20021212. Available from: https://doi.org/10.1101/2020.02.08.20021212
Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. 2020:200823. Available from: https://doi.org/10.1148/radiol.2020 200823
Simpson S, Kay FU, Abbara S, et al. Radiological Society of North America Expert Consensus Statement on Reporting Chest CT Findings Related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiol Cardiothorac Imaging. 2020;2(2): e200152. Available from: https://doi.org/10.1148/ryct.2020200152
Colson P, Rolain J-M, LagierJ-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020:105932. Available from: https://doi.org/10.1016/j.ijantimicag.2020.105932
Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Main point?: Hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit. Clin Infect Dis. 2020;2:1-25.
Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents. 2020:105949. Available from: https://doi.org/10.1016/j.ijantimicag. 2020.105949
Chan JFW, Yanfeng Yao A, Yeung M-L, et al. Treatment with lopinavir/ritonavir or interferon-?1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset. J Infect Dis. 2020;212(12).
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de Creative Commons Reconocimiento- NoComercial- SinObraDerivada 4.0 Internacional. que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.